

ALKYLATION OF ERGOLINE DERIVATIVES AT POSITION N₍₁₎*


Jan ŠMIDRKAL** and †Miroslav SEMONSKÝ

Research Institute for Pharmacy and Biochemistry, 130 60 Prague 3

Received December 29th, 1980

N₍₁₎-Alkyl-8β-ergolines I–XII were prepared by alkylation of 8β-ergoline derivatives XIII to XVIII with alkyl halides in dimethyl sulphoxide in the presence of potassium hydroxide. The compounds I–XII exhibited weak inhibition effects on the secretion of prolactin.

N₍₁₎-Alkylation of ergoline derivatives has so far been effected by exposure of an N₍₁₎ non-substituted derivative to the action of alkyl halide in liquid ammonia containing potassium amide¹. This paper describes syntheses of N₍₁₎-alkyl derivatives of 8β-ergolines, I–XII (Table I), from compounds XIII–XVIII by a procedure analogous to that used for alkylation of indole². The reaction conditions were modified to obtain maximum yields. The alkylation was carried out by the action of alkyl halides in dimethyl sulphoxide in the presence of a base (KOH, NaOH, NaH). The alkyl halide was added to a cooled reaction mixture gradually. In the use of dimethylformamide, hexamethylphosphorictriamide or tetramethylurea, instead of dimethyl sulphoxide, the yields were lower.



I–XII See Table I

- XIII, R¹ = H, R² = CH₃, R³ = CH₃ (ref.⁷)
 XIV, R¹ = H, R² = CH₃, R³ = CH₂CN (ref.⁸)
 XV, R¹ = H, R² = n-C₃H₇, R³ = CH₂CN (ref.³)
 XVI, R¹ = H, R² = CH₃, R³ = CH₂OH (ref.^{5,8})
 XVII, R¹ = H, R² = CH₃, R³ = CH₂CONH₂ (ref.⁹)
 XVIII, R¹ = H, R² = CH₃, R³ = COOH (ref.¹)

* Part LX of the series Ergot Alkaloids; Part LIX: This Journal 45, 755 (1980).

** Present address: Research Institute of Fat Industry, 269 01 Rakovník.

TABLE I
 Derivatives of 1-alkyl-substituted 8 β -ergolines

Compound R ¹	R ² R ³	Procedure yield, %	Formula (m. w.)	M. p., °C (solvent)	$(\alpha)_D^{20}$, c (0.5) (solvent)	Calculated/Found		
						% C	% H	
I	CH ₃	A	C ₁₇ H ₂₂ N ₂ (254.4)	121–123 (CH ₃ OH)	–107 (pyridine)	80.26 80.07	8.72 8.98	11.02 10.98
II ^a	CH ₃	A	C ₁₈ H ₂₁ N ₃ (279.4)	171–173 (C ₂ H ₅ OH)	–103 (pyridine)	77.38 77.62	7.58 7.68	15.04 14.82
III	CH ₃	A	C ₁₉ H ₂₃ N ₃ (293.4)	161–162 (C ₂ H ₅ OH)	–114 (pyridine)	77.78 77.55	7.90 8.09	14.32 14.10
C ₂ H ₅	CH ₂ CN	55						
IV	CH ₃	A	C ₂₀ H ₂₅ N ₃ (307.4)	137–138 (C ₂ H ₅ OH)	–108 (pyridine)	78.13 77.85	8.20 8.46	13.67 13.82
n-C ₃ H ₇	CH ₂ CN	48						
V	n-C ₃ H ₇	A	C ₂₀ H ₂₅ N ₃ (307.4)	127–128 (C ₂ H ₅ OH)	–88 (pyridine)	78.13 78.06	8.20 8.49	13.67 13.97
CH ₃	CH ₂ CN	58						
VI ^b	CH ₃	B	C ₁₇ H ₂₂ N ₂ O (270.4)	250–252 (C ₂ H ₅ OH)	–93 (pyridine)	75.51 75.67	8.20 8.27	10.36 10.18
CH ₃	CH ₂ OH	82						
VII	CH ₃	B	C ₁₈ H ₂₃ N ₃ O (297.4)	261–263 (CH ₃ OH)	–85 (pyridine)	72.69 72.73	7.79 7.74	14.13 14.10
CH ₃	CH ₂ CONH ₂	64						
VIII	CH ₃	B	C ₂₀ H ₂₇ N ₃ O (325.4)	142–144 (CH ₃ OH)	–86 (pyridine)	73.80 73.73	8.36 8.37	12.91 12.99
n-C ₃ H ₇	CH ₂ CONH ₂	42						
IX ^c	CH ₃	C	C ₁₇ H ₂₀ N ₂ O ₂ (284.4)	over 360 (H ₂ O)	–76 (0.1M-NaOH)	71.80 71.64	7.09 7.26	9.85 9.67
CH ₃	COOH	88						
X	CH ₃	C	C ₁₈ H ₂₂ N ₂ O ₂ (298.4)	298–301 (H ₂ O)	–84 (0.1M-NaOH)	72.45 72.36	7.43 7.54	9.39 9.37
C ₂ H ₅	COOH	47						
XI	CH ₃	C	C ₁₉ H ₂₄ N ₂ O ₂ (312.4)	260–262 (H ₂ O)	–84 (0.1M-NaOH)	73.04 72.97	7.74 7.90	8.97 8.82
n-C ₃ H ₇	COOH	35						
XII ^d	CH ₃	C	C ₂₃ H ₂₄ N ₂ O ₂ (362.5)	223–225 (H ₂ O)	–98 (0.1M-NaOH)	76.64 76.59	6.71 6.84	7.77 7.57
C ₆ H ₅ CH ₂	COOH	52						

^a Reported⁴ m.p. 173–175°C, $(\alpha)_D^{20}$ –105° (c 0.5, pyridine); ^b reported⁵ m.p. 243–246°C, $(\alpha)_D^{20}$ –98° (c 0.5, pyridine); ^c reported⁶ $(\alpha)_D^{20}$ –76° (c 0.5, 0.1M-NaOH), ^d reported¹ m.p. 217–222°C, $(\alpha)_D^{20}$ –106° (c 0.5, pyridine).

The effect of the compounds *I–XII* on the secretion of adenohipophyseal prolactin was determined with the aid of the antinidation and antilactation effects. We have found that alkylation at position $N_{(1)}$ leads to a lower activity compared to the non-alkylated compounds^{3–9}. These tests were performed in the Research Institute for Pharmacy and Biochemistry under the direction of Dr K. Řežábek.

EXPERIMENTAL

The melting points, determined on the Boetius block, are not corrected. Analytical samples were dried *in vacuo* (30 Pa) at temperatures corresponding to their melting points. Specific rotations, determined in a polarimeter Perkin–Elmer 141, refer to compounds free of the crystallization solvent. Purity of the compounds was checked by thin-layer-chromatography on silica gel with a luminiscent indicator (Silufol UV₂₅₄, Kavalier), UV light of the wave length 254 nm being used as detector.

Alkylation of 8β-Ergolines

To a mixture of pulverized potassium hydroxide (5.6 g, 0.1 mol) in dimethyl sulphoxide (50 ml), which had been stirred for 10 min, was added a derivative of 8β-ergoline (0.02 mol) at room temperature and the mixture was stirred for 30 min, then cooled down to 17°C. At this temperature an alkyl halide (0.024 mol) was added dropwise under stirring in the course of 5 min (alkyl iodides in the syntheses of compounds *I–III*, *V–VII*, *IX* and *X*, bromides for compounds *IV*, *VIII* and *XI*, and benzyl chloride for *XII*). After another 5 min the solution was poured into 500 ml of water and *A*) extracted with chloroform, the extract was washed with water, dried with MgSO₄, taken to dryness and the residue was crystallized from the solvent given in Table I; *B*) the precipitate was collected on a filter, washed with water and recrystallized from the solvent given in Table I; *C*) the solution was discoloured with active carbon, brought to pH 6 with acetic acid, the precipitate was collected on a filter and dissolved in 2% aqueous ammonia. The solution was acidified with acetic acid to pH 6 and the separated product was collected on a filter, washed with water and dried *in vacuo*.

REFERENCES

1. Troxler F., Hofmann H.: *Helv. Chim. Acta* **40**, 1721 (1957).
2. Heaney H., Ley S. V.: *J. Chem. Soc., Perkin Trans.* **1973**, 199.
3. Křepelka J., Černý A., Kotva R., Semonský M.: *This Journal* **42**, 1209 (1977).
4. Černý A., Řežábek K., Šeda M., Trčka V., Semonský M.: *This Journal* **41**, 1042 (1976).
5. Bernardi L., Boasio G., Elli C., Patteli B., Temperili A.: *Farmaco Ed. Sci. (Pavia)* **30**, 789 (1975).
6. Černý A., Semonský M.: *This Journal* **27**, 1585 (1962).
7. Křepelka J., Semonský M.: *This Journal* **41**, 1416 (1976).
8. Semonský M., Kucharczyk N.: *This Journal* **33**, 577 (1966).
9. Semonský M., Kucharczyk N., Beran M., Řežábek K., Šeda M.: *This Journal* **36**, 2200 (1971).

Translated by J. Salák.